Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reishi & Privet Formula (RPF) is a standardized herbal combination therapy based on Traditional Chinese Medicine (TCM), consisting of sporederm-broken spores of the Reishi mushroom (*Ganoderma lucidum*) and extracts from the Glossy Privet fruit (*Ligustrum lucidum*). Developed and manufactured by Nanjing Zhongke Pharmaceutical, the formula is standardized to contain specific levels of polysaccharides and oleanolic acid. RPF is primarily being evaluated for its ability to improve quality of life, general health, and emotional well-being in patients with non-small cell lung cancer (NSCLC) who are undergoing chemotherapy. Clinical studies, including a Phase II trial in China, suggest that the formula is safe and may provide synergetic benefits in mitigating the side effects of conventional cancer treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on reishi + privet.